Japanese chemical and materials company Zeon is opening a new chapter in biotechnology and analytical services. The company announced that it has set up Zeon BioSolutions to strengthen its presence in healthcare and life sciences, and has acquired an advanced cell analysis business from Knowledge Palette that utilizes Quartz-Seq2 technology. The new entity is positioned to offer transcriptome analysis services to the market.
Transcriptome Analysis Powered by Quartz-Seq2
According to Zeon, the acquired business is built on the Quartz-Seq2 platform, which enables the analysis of gene expression profiles at the single-cell level. The company describes Quartz-Seq2 as “the world’s most accurate cell analysis technology” and stated that Zeon BioSolutions plans to expand its transcriptome analysis services by leveraging this capability.
COP Polymer and Precision Molding at the Core
From a chemistry perspective, the key significance of this development lies in Zeon’s strategy to integrate its biotechnology initiative with its polymer and process technologies. Zeon emphasized that combining the Quartz-Seq2 analytical platform with its precision molding capabilities using cyclo olefin polymers (COP) is expected to generate strong synergies.
COP materials are classified as specialty polymers widely used in life sciences and analytical equipment. Thanks to properties such as low impurity levels, excellent optical performance and chemical resistance, COP is commonly preferred for laboratory consumables, measurement and imaging components, and precision-molded analytical parts. When combined with Zeon’s growing biotechnology service and technology portfolio, this positions the company to expand its role from a materials supplier to a provider of high-value analytical solutions.
Target: Expanding Its Share in Healthcare and Life Sciences
Zeon views this initiative as part of its medium-term growth strategy. Rather than simply adding a new business line, the company aims to bring its chemical materials expertise together with data- and biology-driven analytical technologies within a single framework. In this context, Zeon BioSolutions is expected to serve as a key driver for accelerating new business development in healthcare and life sciences.
Source: zeon.co.jp
